Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc (NQ: FHTX )

4.720 -0.110 (-2.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 91,534
Open 4.890
Bid (Size) 4.650 (2)
Ask (Size) 7.560 (2)
Prev. Close 4.830
Today's Range 4.660 - 4.900
52wk Range 4.510 - 18.12
Shares Outstanding 36,936,886
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Foghorn Therapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
From Foghorn Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
-27.38%
-27.38%
1 Month
-16.46%
-16.46%
3 Month
-21.98%
-21.98%
6 Month
-46.49%
-46.49%
1 Year
-64.96%
-64.96%

More News

Read More
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
From Foghorn Therapeutics, Inc.
Via Globe NewsWire
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
Via The Motley Fool
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
From Foghorn Therapeutics, Inc.
Via Globe NewsWire
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
From Foghorn Therapeutics, Inc.
Via Globe NewsWire
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
From Foghorn Therapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
From Foghorn Therapeutics, Inc.
Via Globe NewsWire
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
From Foghorn Therapeutics, Inc.
Via Globe NewsWire
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via Globe NewsWire
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
From Foghorn Therapeutics, Inc.
Via Globe NewsWire
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
From Foghorn Therapeutics, Inc.
Via Globe NewsWire
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
From Foghorn Therapeutics, Inc.
Via Globe NewsWire
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022
Via Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Via Benzinga
Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday
Via Benzinga
Dow Drops Over 100 Points; Aerie Pharmaceuticals Shares Spike Higher
Via Benzinga
Twitter, Zoom Video And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Nasdaq Turns Lower; Crude Oil Rises Sharply
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.